Oxygen or cooling, to make a decision after acute ischemia stroke

Wen-cao Liu¹, Xin-chun Jin², *

1 Department of Emergency, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi Province, China
2 Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
*Correspondence to: Xin-chun Jin, M.D., xinchunjin@gmail.com.

Abstract

The presence of a salvageable penumbra, a region of ischemic brain tissue with sufficient energy for short-term survival, has been widely agreed as the premise for thrombolytic therapy with tissue plasminogen activator (tPA), which remains the only United States Food and Drug Administration (FDA) approved treatment for acute ischemia stroke. However, the use of tPA has been profoundly constrained due to its narrow therapeutic time window and the increased risk of potentially deadly hemorrhagic transformation (HT). Blood brain barrier (BBB) damage within the thrombolytic time window is an indicator for tPA-induced HT and both normobaric hyperoxia (NBO) and hypothermia have been shown to protect the BBB from ischemia/reperfusion injury. Therefore, providing the O₂ as soon as possible (NBO treatment), freezing the brain (hypothermia treatment) to slow down ischemia-induced BBB damage or their combined use may extend the time window for the treatment of tPA. In this review, we summarize the protective effects of NBO, hypothermia or their use combined with tPA on ischemia stroke, based on which, the combination of NBO and hypothermia may be an ideal early stroke treatment to preserve the ischemic penumbra. Given this, there is an urge for large randomized controlled trials to address the effect.

Key words: normobaric hyperoxia; hypothermia; ischemic stroke; tissue plasminogen activator; neuroprotection; blood brain barrier; thrombolysis; hemorrhage transformation

doi: 10.4103/2045-9912.196902

How to cite this article: Liu WC, Jin XC (2016) Oxygen or cooling, to make a decision after acute ischemia stroke. Med Gas Res 6(4):206-211.

Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Funding: This work was supported by Soochow University Research Startup Funds to JX (Q 421500113) and the Priority Academic Program Development of Jiangsu Higher Education Institutions of China.

Introduction

Acute ischemic stroke (AIS) is the most common form of stroke and an almost immediate loss of oxygen and glucose to the brain tissue occurred when blood vessel is suddenly occluded by a thrombus or embolism (Lakhan et al., 2013). Ischemic penumbra is a region of ischemic brain tissue with sufficient energy for short-term survival (Hakim, 1998) and if ischemia duration is extended, the penumbra will progress to irreversible damage (Dimagl et al., 1999). Therefore, the primary goal of current treatment for AIS is to salvage the penumbra (Ramos-Cabrer et al., 2011), which has inspired the development of two main categories of drugs to treat AIS: some drugs to interrupt cell death pathways (Reza Noorian et al., 2011) and other drugs to induce reperfusion (Barreto and Alexandrov, 2012). Over decades, research has failed to translate over 1,000 experimental treatments from discovery in cells and rodents to use in humans (O’Collins et al., 2012) and a major goal in the treatment of AIS is to prompt arterial recanalization. Until now, thrombolysis with tissue plasminogen activator (tPA) within 3 or 4.5 hours...
after symptom onset is the only approved treatment by the United States Food and Drug Administration (FDA) for AIS (Hacke et al., 2008; Del Zoppo et al., 2009; Peplow, 2015). However, brief therapeutic window and the high incidence of hemorrhage transformation (HT) have profoundly constrained the clinical use of tPA in ischemic stroke patients (Marshall, 2015).

The presence of a salvageable penumbra has been widely agreed as the premise for thrombolytic therapy (Ramos-Cabrera et al., 2011), while protecting the blood brain barrier (BBB) is critical to avoid brain edema and HT following reperfusion therapy. In the early stage of AIS, ischemia-induced hypoxia and the consequent bioenergetic failure produced irreversible damage to the penumbra, and BBB damage within the thrombolytic time window is an indicator for tPA-induced HT (Jin et al., 2014; Leigh et al., 2014). Therefore, either providing the O$_2$ as soon as possible (normobaric hyperoxia (NBO) treatment), freezing the brain (hypothermia) to slow down the ischemia-induced damage or both treatments will extend the time window of tPA treatment.

**Effect of NBO Treatment**

**NBO’s protective effect**

Improving tissue oxygenation has been studied for many years as a simplistic but plausible treatment strategy to reduce ischemia-induced injury. Recent animal and human stroke studies showed that when administered early after ischemia onset, NBO showed neuroprotective effects (Qi et al., 2013). For example, NBO retards the evolution of ischemic brain tissue toward infarction in a rat model of transient focal cerebral ischemia (Xu et al., 2016). This protection is attributed to NBO’s ability to improve energy metabolism in the ischemic penumbra, as evidenced by elevated interstitial oxygen partial pressure (Liu et al., 2006), increased cerebral blood flow and O$_2$ delivery (Chazalviel et al., 2016c), reductions in acidosis and adenosine triphosphate (ATP) deletion (Sun et al., 2011), and reduced caspase-3 and -9 expression (Chen et al., 2015). Of note, continued NBO treatment after reperfusion shows more beneficial effects than NBO treatment during occlusion alone (Tiwari et al., 2016).

**Side effect and controversy of NBO**

As NBO is readily available, safe and can be initiated promptly after stroke onset by paramedics, it has been suggested as a practical acute-phase treatment to slow down the onset of irreversible damage of the penumbra, thus potentially allowed for delayed or more effective thrombolysis (Kim et al., 2005; Henninger and Fisher, 2006; Liu et al., 2009). In addition, NBO has been shown as an effective neuroprotective strategy for ischemic stroke (Cornet et al., 2012; Qi et al., 2013; Shi et al., 2016). However, recent clinical trial was terminated because of unclear therapeutic efficacy (95 % NBO in AIS) (Cornet et al., 2012; Pountain and Roffe, 2012). In addition, in a recent Indian trial using 61 % NBO for anterior circulation ischemic strokes patients within 12 hours after stroke, NBO did not significantly improve their clinical outcome (Padma et al., 2011). This is maybe due to the complexity of stroke and detrimental potential of oxygen-associated excessive generation of reactive oxygen series (ROS). However, a recent critical review of the literature showed that NBO does not increase ROS or oxidative stress if applied for a short duration; therefore, the potential that NBO is a viable neuroprotective strategy for AIS is compelling. The benefits of NBO may significantly outweigh the risks of potential increase in ROS generation for the treatment of AIS (Weaver and Liu, 2015).

**Combination treatment with NBO**

Since NBO alone did not work as expected, combination NBO with other therapy may be an ideal strategy (Liang et al., 2016). For example, recent studies showed that NBO extended neuro- and vaso-protection of N-acetylcysteine in transient focal ischemia (Liu et al., 2016), combination of NBO and melatonin demonstrated more protective effect on reperfusion injury through regulation cerebral microcirculation (Beker et al., 2015). In addition, combination therapy of NBO with methylene blue improved functional outcome and reduced infarct volume compared to either treatment alone and these improvements extended up to 28 days (Rodriguez et al., 2016).

**Effect of hyperbaric oxygen (HBO) treatment**

HBO is an efficacious, benign and humanitarian way to promote brain repair (Stoller, 2015). It has showed protective effect on traumatic brain injury (Hu et al., 2016). Of note, HBO increased tPA-induced thrombolysis *in vitro*, and reduced ischemic brain damage and edema in rats subjected to thromboembolic brain ischemia (Chazalviel et al., 2016b). In addition, HBO, but not NBO, reduced oxygen and glucose deprivation-induced cell injury (Chazalviel et al., 2016a). More interestingly, numerous basic and clinical studies have shown the beneficial effect of HBO on neurological outcome after stroke; however, HBO’s effect in human stroke is still not sufficiently evidence-based, due to the insufficient randomized double-blind controlled clinical studies (Zhai et al., 2016).

**Effect of NBO treatment with tPA thrombolysis**

NBO could increase the safety of delayed tPA thrombolysis
in stroke (Liu et al., 2009) and has been shown to slow BBB damage and expand the therapeutic time window for tPA treatment in cerebral ischemia (Liang et al., 2015). More importantly, it did not increase cellular markers of superoxide generation or brain levels of matrix metalloprotein-9 (MMP-9) (Kim et al., 2005). Despite producing cerebral blood flow restoration, combination of NBO with tPA had no neuroprotective effect on ischemic brain damage (David et al., 1985); however, Henninger et al. (2009) showed that the combination of NBO with tPA did not increase hemorrhage volume at 10 hours or petechial hemorrhages at 24 hours in a clinically relevant thromboembolic rat stroke model.

**Effect of Hypothermia Treatment**

**Hypothermia’s protective effect**

Hypothermia has been suggested to be the most potent therapeutic approach to reduce experimental ischemic brain injury, and mild hypothermia (MH) is increasingly used for neuroprotection during neurovascular surgery. Mild to moderate hypothermia prevented microvascular basal lamina antigen loss in experimental focal cerebral ischemia (Hamann et al., 2004) and tPA-related hemorrhage after experimental stroke (Tang et al., 2013), reduced infarct volume and BBB breakdown following tPA treatment in the mouse (Cechmanek et al., 2015), diminished oxidative DNA damage and pro-death signaling events after cerebral ischemia (Ji et al., 2007). Hypothermia also established a lasting inhibitory effect on activation of astrogliosis (Zgavc et al., 2012).

Since cooling therapy may reduce damage and potentially improve outcome, MH is a promising neuroprotective therapy in stroke management. In addition, head cooling targets the site of injury and may have fewer side effects than systemic cooling (Kollmar and Schwab, 2012).

**Controversy of delayed hypothermia treatment**

Perhaps the best studied neuroprotective treatment in ischemia models is MH. Extensive data showed that hypothermia lead to decreased infarct volumes and improved outcomes in ischemic animal models (Choi et al., 2012). Despite these findings, MH application in ischemic stroke has been limited by delayed cooling onset, prolonged duration, extensive medical and nursing efforts, and significant complications (Han et al., 2015).

Although a large pool of evidence has demonstrated that MH is beneficial if it is given during cerebral ischemia, there are also controversial reports. For example, in embolic model, inflammatory reactions occurring in the brain after ischemia may contribute to secondary damage (Wang et al., 2002). Delayed administration of minocycline alone or delayed minocycline plus delayed MH reduced the infarction volume significantly (Wang et al., 2003). However, delayed MH alone was not protective and delayed MH in combination with minocycline did not show any additive effects (Wang et al., 2002; Wang et al., 2003).

**Combination treatment with hypothermia**

The proposed combination therapy, which is based on pathophysiological considerations, seems to be a promising alternative for neuroprotection in cerebrovascular surgery (Zausinger et al., 2003). Combination of therapeutic hypothermia and other neuroprotective strategies after ischemic cerebral insult has been reviewed (Goossens and Hachimi-Idrissi, 2014). Combined MH and decompressive craniectomy (DC) result in additional reduction of infarction size and improve neurological score (Doerfler et al., 2001). In addition, MH plus DC not only ameliorates neuron apoptosis but also remarkably reduces infarction size (Jieyong et al., 2006). Shuaib et al. (1993) showed that when CGS-19755, an N-methyl-D-aspartic acid (NMDA) receptor blocker, was combined with MH, the effects of repetitive ischemia were completely abolished in all but one gerbil. Combination of hypothermia with MH may further enhance this protection. Nito et al. (2004) showed that combination of MH with FK506, an immunosuppressant, significantly reduced ischemic brain damage following transient middle cerebral artery occlusion in rats, and expanded the therapeutic window of FK506. Sahin et al. (2010) demonstrated that the combination of citicoline with MH was more effective than either alone in ameliorating cerebral damage after transient focal ischemia by suppressing apoptotic processes. Berger et al. (2004) provided evidence that combining MH and brain-derived neurotrophic factor (BDNF) in the acute stage of ischemia had a synergistic effect in attenuating striatal glutamate release and reducing early infarct size.

**Mild hypothermia with tPA thrombolysis**

Hypothermia is neuroprotective in experimental stroke and may extend the so far limited therapeutic time window for thrombolysis. MH reduced tPA-related hemorrhage and BBB disruption after experimental stroke (Tang et al., 2013). When MH and thrombolysis was combined in experimental thromboembolic stroke, there was no significant difference between the use of t-PA alone or in combination with hypothermia (Kollmar et al., 2004).

**Combination of Oxygen With Cooling**

Issues must be addressed before hypothermia treatment is implemented at a clinical level (Han et al., 2015). Combination therapy of NBO with MH prevented brain damage from thromboembolic stroke via protein kinase C-protein kinase B-nitric oxide metabolite (PKC-AKT-NOX) modulation,
reduced hyperglycolysis and modulated pyruvate dehydrogenase complex in thromboembolic cerebral ischemia (Cai et al., 2016a, b, c). Of note, therapeutic effect of tPA in ischemic stroke was enhanced in combination with NBO and hypothermia (Ji et al., 2015); therefore, it is reasonable to combine NBO and MH after acute ischemia stroke.

**CONCLUSION**

As NBO and MH are widely available and can be promptly initiated after stroke onset, combination of NBO and MH may be an ideal early stroke treatment to preserve the ischemic penumbra, followed by other neuroprotectants to eventually salvage the ischemic penumbral tissue. Because of the high translational degree of both NBO and MH (they are cost-effective, easy to manage, simple to administer, and readily available), there is an urge for large randomized controlled trials to address the effect.

**Author contributions**

WCL reviewed the studies, wrote up the manuscript. XCJ participated in the overall design of the review and obtained partial funding. All authors have read and approved the final version of this paper.

**Conflicts of interest**

The authors declare no competing financial interests

**Plagiarism check**

This paper was screened twice using CrossCheck to verify originality before publication.

**Peer review**

This paper was double-blinded and stringently reviewed by international expert reviewers.

**REFERENCES**

Barreto AD, Alexandrov AV (2012) Adjunctive and alternative approaches to current reperfusion therapy. Stroke 43:591-598.

Beker MC, Caglayan AB, Kelestemur T, Caglayan B, Yalcin E, Yulug B, Kilic U, Hermann DM, Kilic E (2015) Effects of normobaric oxygen and melatonin on reperfusion injury: role of cerebral microcirculation. Oncotarget 6:30604-30614.

Berger C, Schabitz WR, Wolf M, Mueller H, Sommer C, Schwab S (2004) Hypothermia and brain-derived neurotrophic factor reduce glutamate synergistically in acute stroke. Exp Neurol 185:305-312.

Cai L, Thibodeau A, Peng C, Ji X, Rastogi R, Xin R, Singh S, Geng X, Rafols JA, Ding Y (2016a) Combination therapy of normobaric oxygen with hypothermia or ethanol modulates pyruvate dehydrogenase complex in thromboembolic cerebral ischemia. J Neurosci Res 94:749-758.

Cai L, Stevenson J, Geng X, Peng C, Ji X, Xin R, Rastogi R, Sy C, Rafols JA, Ding Y (2016b) Combining normobaric oxygen with ethanol or hypothermia prevents brain damage from thromboembolic stroke via PKC-Akt-NOX modulation. Mol Neurobiol doi: 10.1007/s12035-016-9695-7.

Cai L, Stevenson J, Peng C, Xin R, Rastogi R, Liu K, Geng X, Gao Z, Ji X, Rafols JA, Ji Z, Ding Y (2016c) Adjutant therapies using normobaric oxygen with hypothermia or ethanol for reducing hyperglycolysis in thromboembolic cerebral ischemia. Neuroscience 318:45-57.

Ceclmanek BK, Tuor UI, Rushforth D, Barber PA (2015) Very mild hypothermia (35 degrees c) postischemia reduces infarct volume and blood/brain barrier breakdown following tpa treatment in the mouse. Ther Hypothermia Temp Manag 5:203-208.

Chazalviel L, Blatteau JE, Vallee N, Risso JJ, Besnard S, Abrajin JH (2016a) Effects of normobaric versus hyperbaric oxygen on cell injury induced by oxygen and glucose deprivation in acute brain slices. Med Gas Res 6:169-173.

Chazalviel L, Haelewyn B, Degoulet M, Blatteau JE, Vallee N, Risso JJ, Besnard S, Abrajin JH (2016b) Hyperbaric oxygen increases tissue-plasminogen activator-induced thrombolysis in vitro, and reduces ischemic brain damage and edema in rats subjected to thromboembolic brain ischemia. Med Gas Res 6:64-69.

Chazalviel L, David HN, Haelewyn B, Blatteau JE, Vallee N, Risso JJ, Besnard S, Abrajin JH (2016c) The underestimated effect of normobaric hyperoxia on cerebral blood flow and its relationship to neuroprotection. Brain doi:10.1093/brain/aww178.

Chen S, Peng H, Rowat A, Gao F, Zhang Z, Wang P, Zhang W, Wang X, Qu L (2015) The effect of concentration and duration of normobaric oxygen in reducing caspase-3 and -9 expression in a rat-model of focal cerebral ischaemia. Brain Res 1618:205-211.

Choi KE, Hall CL, Sun JM, Wei L, Mohamad O, Dix TA, Yu SP (2012) A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice. FASEB J 26:2799-2810.

Cornet AD, Kooter AJ, Peters MJ, Smulders YM (2012) Suplemental oxygen therapy in medical emergencies: more harm than benefit? Arch Intern Med 172:289-290.

David HN, Haelewyn B, Degoulet M, Colomb DG Jr, Risso JJ, Abrajin JH (1985) Prothrombolytic action of normobaric oxygen given alone or in combination with recombinant tissue-plasminogen activator in a rat model of thromboembolic stroke. J Appl Physiol (1985) 112:2799-2810.

Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 40:2945-2948.

Dinagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 22:391-397.

Doerfler A, Schwab S, Hoffmann TT, Engelhorn T, Forsting M (2012) Very mild hypothermia (35 degrees c) postischemia reduces infarct volume after permanent focal ischemia in rats. Stroke 33:2675-2681.

Goossens J, Hachimi-Idrissi S (2014) Combination of therapeutic hypothermia and other neuroprotective strategies after an ischemic cerebral insult. Curr Neuropharmacol 12:399-412.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghi Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317-1329.
Liang LJ, Yang JM, Jin XC (2016) Cocktail treatment, a promising strategy to treat acute cerebral ischemic stroke? Med Gas Res 6:33-38.

Liu S, Liu W, Ding W, Miyake M, Rosenberg GA, Liu KJ (2006) Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. J Cereb Blood Flow Metab 26:1274-1284.

Liu W, Hendren J, Qin XJ, Liu KJ (2009) Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke 40:2526-2531.

Liu Y, Liu WC, Sun Y, Shen X, Wang X, Shu H, Pan R, Liu CF, Liu W, Liu KJ, Jin X (2016) Normobaric hyperoxia extends neuro- and vaso-protection of N-acetylcysteine in transient focal ischemia. Mol Neurobiol doi:10.1007/s12035-016-9932-0.

Marshall RS (2015) Progress in intravenous thrombolytic therapy for acute stroke. JAMA Neurol 72:928-934.

Nito C, Kamiya T, Ueda M, Arii T, Katayama Y (2004) Mild hypothermia enhances the neuroprotective effects of FKS06 and expands its therapeutic window following transient focal ischemia in rats. Brain Res 1008:179-185.

O'Collins VE, MacLeod MR, Donnan GA, Howells DW (2012) Evaluation of combination therapy in animal models of cerebral ischemia. J Cereb Blood Flow Metab 32:585-597.

Padma MV, Bhasin A, Bhatia R, Garg A, Singh MB, Tripathi M, Prasad K (2011) Normobaric oxygen therapy in acute ischemic stroke: A pilot study in Indian patients. Ann Indian Acad Neurol 13:284-288.

Peplow PV (2015) Neuroimmunomodulatory effects of transcranial laser therapy combined with intravenous tPA administration for acute cerebral ischemic injury. Neural Regen Res 10:1186-1190.

Pountain SJ, Roffe C (2012) Does routine oxygen supplementation in patients with acute stroke improve outcome? BMJ 345:e6976.

Qi Z, Liu W, Luo Y, Ji X, Liu KJ (2013) Normobaric hyperoxia-based neuroprotective therapies in ischemic stroke. Med Gas Res 3:2.

Ramos-Cabrero P, Campos F, Sobrino T, Castillo J (2011) Targeting the ischemic penumbra. Stroke 42:282-288.

Reza Noorian A, Nogueira R, Gupta R (2011) Neuroprotection in acute ischemic stroke: Where to go? Exp Neurol 272:67-77.

Rodriguez P, Zhao J, Milman B, Tiwari YV, Duong TQ (2016) Methylene blue and normobaric hyperoxia combination therapy in experimental ischemic stroke. Brain Behav 6:e00478.

Sahin S, Alkan T, Temel SG, Tureyen K, Tolunay S, Korol F (2010) Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischemia in rats. J Clin Neurosci 17:227-231.

Shi SH, Qi ZF, Luo YM, Ji XM, Liu KJ (2016) Normobaric oxygen treatment in acute ischemic stroke: a clinical perspective. Med Gas Res 6:147-153.

Shuaib A, Ijaz S, Mazagri R, Senthilsevelan A (1993) CGS-19755 is neuroprotective during repetitive ischemia: this effect is significantly enhanced when combined with hypothermia. Neuroscience 56:915-920.

Stoller KP (2015) All the right moves: the need for the timely use of hyperbaric oxygen therapy for treating TBI/CTE/PTSD. Med Gas Res 5:7-12.

Sun L, Strelow H, Mies G, Veltkamp R (2011) Oxygen therapy improves energy metabolism in focal cerebral ischemia. Brain Res 1415:103-108.
Tang XN, Liu L, Koike MA, Yenari MA (2013) Mild hypothermia reduces tissue plasminogen activator-related hemorrhage and blood brain barrier disruption after experimental stroke. Ther Hypothermia Temp Manag 3:74-83.

Tiwari YV, Jiang Z, Sun Y, Du F, Rodriguez P, Shen Q, Duong TQ (2016) Effects of stroke severity and treatment duration in normobaric hyperoxia treatment of ischemic stroke. Brain Res 1635:121-129.

Wang CX, Yang T, Shuaib A (2003) Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res 963:327-329.

Wang CX, Yang T, Noor R, Shuaib A (2002) Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol 2:2.

Weaver J, Liu KJ (2015) Does normobaric hyperoxia increase oxidative stress in acute ischemic stroke? A critical review of the literature. Med Gas Res 5:11.

Xu J, Zhang Y, Liang Z, Wang T, Li W, Ren L, Huang S, Liu W (2016) Normobaric hyperoxia retards the evolution of ischemic brain tissue toward infarction in a rat model of transient focal cerebral ischemia. Neurol Res 38:75-79.

Zausinger S, Westermaier T, Plesnila N, Steiger HJ, Schmid-Elsaesser R (2003) Neuroprotection in transient focal cerebral ischemia by combination drug therapy and mild hypothermia: comparison with customary therapeutic regimen. Stroke 34:1526-1532.

Zgavc T, Ceulemans AG, Hachimi-Idrissi S, Kooijman R, Sarre S, Michotte Y (2012) The neuroprotective effect of post ischemic brief mild hypothermic treatment correlates with apoptosis, but not with gliosis in endothelin-1 treated rats. BMC Neurosci 13:105.

Zhai WW, Sun L, Yu ZQ, Chen G (2016) Hyperbaric oxygen therapy in experimental and clinical stroke. Med Gas Res 6:111-118.